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Abstract: OBJECTIVES Tumor thickness and tumor volume measured by computed tomography (CT)
were suggested as valuable prognosticator for patients’ survival diagnosed with malignant pleural mesothe-
lioma (MPM). The purpose was to assess the accuracy of CT scan based preoperatively measured tumor
volume and thickness compared to actual tumor weight of resected MPM specimen and pathologically
assessed tumor thickness, as well as an analysis of their impact on overall survival (OS). METHODS
Between 09/2013-08/2018, 74 patients were treated with induction chemotherapy followed by (extended)
pleurectomy/decortication ((E)PD). In 53 patients, correlations were made between CT-measured vol-
ume and -tumor thickness (cTV and cTT) and actual tumor weight (pTW) based on the available values.
Further cTV and pT/IMIG stage were correlated using Pearson correlation. Overall survival (OS) was cal-
culated with Kaplan Meier analysis and tested with log rank test. For correlation with OS Kaplan-Meier
curves were made and log rank test was performed for all measurements dichotomized at the median.
RESULTS Median pathological tumor volume (pTV) and pTW were 530 ml [130 ml - 1000 ml] and 485
mg [95 g - 982 g] respectively. Median (IQR) cTV was 77.2 ml (35.0-238.0), median cTT was 9.0 mm
(6.2-13.7). Significant association was found between cTV and pTV (R = 0.47, p < 0.001) and between
cTT and IMIG stage (p = 0,001) at univariate analysis. Multivariate regression analysis revealed, that
only cTV correlates with pTV. Median follow-up time was 36.3 months with 30 patients dead at the time
of the analysis. Median OS was 23.7 months. 1-year and 3-year survival were 90 and 26% respectively
and only the cTV remained statistically associated with OS. CONCLUSION Preoperatively assessed CT
tumor volume and actual tumor volume showed a significant correlation. CT tumor volume may predict
pathological tumor volume as a reflection of tumor burden, which supports the integration of CT tumor
volume into future staging systems.
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Abstract
Objectives: Tumor thickness and tumor volume measured by computed tomography (CT) were suggested as
valuable prognosticator for patients’ survival diagnosed with malignant pleural mesothelioma (MPM). The purpose
was to assess the accuracy of CT scan based preoperatively measured tumor volume and thickness compared to
actual tumor weight of resected MPM specimen and pathologically assessed tumor thickness, as well as an analysis
of their impact on overall survival (OS).
Methods: Between 09/2013–08/2018, 74 patients were treated with induction chemotherapy followed by
(extended) pleurectomy/decortication ((E)PD). In 53 patients, correlations were made between CT-measured volume
and -tumor thickness (cTV and cTT) and actual tumor weight (pTW) based on the available values. Further cTV and
pT/IMIG stage were correlated using Pearson correlation. Overall survival (OS) was calculated with Kaplan Meier
analysis and tested with log rank test. For correlation with OS Kaplan-Meier curves were made and log rank test
was performed for all measurements dichotomized at the median.
Results: Median pathological tumor volume (pTV) and pTW were 530 ml [130 ml – 1000 ml] and 485 mg [95 g –
982 g] respectively. Median (IQR) cTV was 77.2 ml (35.0–238.0), median cTT was 9.0 mm (6.2–13.7). Significant
association was found between cTV and pTV (R = 0.47, p < 0.001) and between cTT and IMIG stage (p = 0,001) at
univariate analysis. Multivariate regression analysis revealed, that only cTV correlates with pTV. Median follow-up
time was 36.3 months with 30 patients dead at the time of the analysis. Median OS was 23.7 months. 1-year and 3-
year survival were 90 and 26% respectively and only the cTV remained statistically associated with OS.
Conclusion: Preoperatively assessed CT tumor volume and actual tumor volume showed a significant correlation.
CT tumor volume may predict pathological tumor volume as a reflection of tumor burden, which supports the
integration of CT tumor volume into future staging systems.
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Introduction
Malignant pleural mesothelioma (MPM) is an aggressive
tumor with a median overall survival (OS) of 9 to 12
months [1]. It is strongly correlated with asbestos
exposure with a long latency period [2, 3]. Despite the
clear identification of this risk factor and the measures
adopted to ban asbestos from construction industries,
the MPM peak of incidence has not been reached yet,
and it is expected in 2030 in developed countries [2].
Current guidelines [3–8] recommend a multimodality
therapy approach in selected patients, consisting of in-
duction chemotherapy followed by macroscopic
complete resection (MCR) and/or adjuvant chemo- or
radiotherapy. Surgical candidates must be carefully eval-
uated. Accurate clinical staging is at this point essential.
The latter point is crucial and rather difficult to achieve,
as the TNM staging system showed some flaws in clin-
ical application. In fact, there is a poor correspondence
between clinical and pathologic stage and the system it-
self lacks of prognostic significance, specifically for T1
and T2 disease. The use of strict criteria taking into ac-
count a precise segmentation of the CT scans by obtain-
ing a surrogate for the tumor burden, has shown to have
prognostic significance [9]. This is because the TNM is
mostly based on surgical cases where the tumor invasion
is assessed microscopically; in clinical practice, the dis-
tinction between parietal and visceral pleural involve-
ment is not feasible with the current imaging modalities
[10]. To overcome this problem, there has been a great
interest in finding different clinical predictors that can
serve as surrogate of the pathological measurement and
help to stratify patients for enrollment in treatment
protocols.
Quantitative assessment of the tumor burden has
been evaluated as a potential predictor. Computed
tomography (CT)-tumor volume has been proven to
be a reliable prognosticator [11]. In contrast to most
solid malignancies in which the mono-dimensional
criterion is used, the volumetric analysis has shown
to be more reliable in terms of inter- and intra-
observer variability [12].
The aim of the present study was to assess the correl-
ation of CT based tumor burden representative parame-
ters with pathological measurement of the overall tumor
burden.
Patients and methods
We retrospectively analyzed CT scans as well as clinical
and pathological records of patients treated for MPM at
our institution from 09/2013 to 08/2018. The main ob-
jective of the study was to verify the correlation between
CT descriptors and pathological findings in order to
identify robust imaging derived clinical predictors of
pathological measurements and which are available
before surgery. Secondary end-point of the study was
the correlation between CT descriptors and overall sur-
vival in our population.
All patients included underwent induction chemother-
apy (platin-based chemotherapy/pemetrexed) followed
by (extended) pleurectomy/decortication ((E)PD). Pa-
tients with incomplete data on CT descriptors, patho-
logical descriptors and survival were excluded from the
analysis. Local ethics committee approval was given for
analysis of the mesothelioma database (StV 29–2009,
EK-ZH 2012–0094). All patients signed written informed
consent. All patient data was anonymized.
CT-based tumor thickness and volume
All CT examinations were performed using different
types of multidetector CT scanner (Somatom Flash,
Somatom Force and Somatom Definition AS, Siemens,
Erlangen Germany) before and after induction therapy.
A standard chest CT protocol was applied with contrast
agent. Section thickness was 2.5 mm with an increment
of 2 mm. For the purpose of the study we only used the
CT scan after chemotherapy/before surgery, for analysis
median time between CT scan and surgery was 4 weeks.
CT descriptors were tumor thickness (cTT) and tumor
volume (cTV). Tumor thickness was defined as the sum
of the two thickest spots on axial section plane (perpen-
dicular to the chest wall or mediastinum) each measured
at three representative different levels (optimally at
lower, middle, and upper level if feasible) given in mm,
with at least measurements being performed at 2
different levels for each patient. cTV was derived semi-
automatically on axial planes of the CT scan. The quan-
tification of tumor volume was previously described by
Frauenfelder et al. [12]. On every fifth to tenth CT sec-
tion, respectively, the tumor contour was drawn semi-
automatically by applying a live-wire algorithm using
dedicated post-processing software (Myrian®; Intrasense,
Paris, France). The contours in between were obtained
by linear interpolation. The results were reviewed and
were adjusted if necessary by two experienced chest ra-
diologists (Prof. Frauenfelder and Dr. Nguyen-Kim). The
software calculated the volume of the tumor by summar-
izing all voxels and multiplied by the voxel size.
Pathology-based volume
Pathological samples were weighted directly in the oper-
ating room as well as volume was taken, before it was
sent to the Institute of Pathology. Tumor volume was
measured by assessing the specimen into a bowl filled
with saline, the displaced fluid indicated the volume. In-
formation on tumor weight (TW) are given in gram (g)
and the total tumor volume (pTV) in milliliter (ml).
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Pathology-based staging
Pathological staging was assigned according to the 8th
TNM classification and IMIG staging system [5] and for
a better overview IMIG stage I and II were combined
and referred to as “low stage” and stage III and IV as
“high stage”. Overall survival (OS) was calculated from
the start of chemotherapy to the date of death for any
cause, with living patients censored at the date of last
follow-up.
Statistical analysis
Due to the very high correlation between pTV and TW
(Pearson r = 0.94, p < 0.001), only pTV remained in the
analysis to assess the predictability of the pathological
variables given cTV and cTT, respectively.
Due to the non-normality of cTV and cTT the Kendall
rank correlation coefficient was used to assess the associ-
ation with pTV. The IMIG stage with levels I to IV was
combined into a two-level factor. The stages I and II were
combined into a “low” IMIG stage group, while stages III
and IV were combined into a “high” IMIG stage group.
This seemed sensible due to the low number of patients in
some strata as well as for comparability with previous
studies. Therefore a Wilcoxon-Mann-Whitney test was
performed to assess its correlation with cTV and cTT.
Patient OS was assessed by Kaplan-Meier method. To
assess the importance of pathological and clinical predic-
tors separately two multiple Cox’s proportional hazard
models were fitted to the data, firstly including patho-
logical covariates pTV and IMIG stage, secondly includ-
ing cTV and cTT. Two separate models were fitted in
order to avoid highly correlated independent covariates
in the same model and to observe which set of covari-
ates explained survival times better.
Statistical significance was set at a p-value of p < 0.05.
Data processing and analysis were performed with the
statistical R-software version 3.6.2. The dataset support-
ing the conclusions of this article is included within the
article. Additional data can be supplied on request.
Results
Eighty-four patients underwent induction chemotherapy
(platin-based chemotherapy/pemetrexed) followed by
macroscopic complete resection (MCR) during the study
period. Seventy-four patients underwent induction
chemotherapy followed by (E)PD. In 53 patients all pa-
rameters (cTT, cTV, pTV, pTW, IMIG stage) were avail-
able for analyses. To be mentioned, that resected
diaphragm and pericardium was included, in case of
EPD in 49 patients. Patients’ characteristics are shown in
Table 1. Median time between restaging CT or PET/CT
and surgery was 24 days [1–90 days].
Response rate after induction chemotherapy showed in
the majority of the cases a stable disease (n = 32) and
partial response (n = 14). The pathological stage distribu-
tion, as seen in Table 1, showed 6 patients with postop-
erative stage IV which mainly was due to an
intraoperative proven infiltration of the chest wall. As
Table 1 Patient characteristics
Covariate Overall
(n = 53)










Packyear (median [Range]) 30 [0–100]
Right laterality (%) 36 (67.9)
Type of surgery (%)
EPD 49 (92.5)
P/D 3 (5.7)
Extended parietal pleurectomy 1 (1.9)
Response
Stable disease 32 (60.4)
Partial regression 14 (26.4)
Progressive disease 4 (7.5)
Unknown 3 (5.7)
IMIG stage (%)
I (low) 5 (9.4)
II (low) 6 (11.3)
III (high) 36 (67.9)
IV (high) 6 (11.3)












lost follow up 2 (3.8)
NS Not significant
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this was the case in a maximum of 1–2 spots, the deci-
sion was made for completion of the surgery and the re-
section margins at the chest wall were marked with clips
intraoperatively. Overall, our macroscopic complete re-
section achievement was completed for 51 patients and
2 patients of missing data.
Median pTV and TW were 530ml [130 ml – 1000 ml]
and 485 mg [95 g – 982 g] respectively. Median (IQR)
cTV was 77.2 ml (35.0–238.0), median cTT was 9.0 mm
(6.2–13.7) (Table 2).
Significant association was found between cTV and
pTV (p < 0.001) and between cTT and IMIG stage (p =
0,001) at univariate analysis. Further multivariate regres-
sion analysis including cTV and cTT confirmed, that
only cTV remained correlated with pTV. Higher CT vol-
ume seems to be associated with higher pathological vol-
ume. Additionally, patients with higher IMIG stage have
a higher tumor thickness. CT tumor thickness, does not
result in additional information if CT tumor volume is
given (p = 0,21) to predict pathological tumor volume as
a reflection of tumor burden (Figs. 1, 2 and 3).
Median follow up time was 36.3 months [CI 95% LCL:
23.6 months and UCL: 47.7 months] with 30 patients
dead at the time of the analysis. Median OS was 23.7
months [CI 95% LCL: 17.9 months and UCL: 34 months]
(Fig. 4), 1-year and 3-year survival were 90 and 26%,
respectively.
When fitting two separate Cox Proportional-Hazards
models for clinical and pathological covariates to the
data, out of the four fitted parameters only the coeffi-
cient for cTV remained statistically significant (HR:
1.002, p = 0,02). The overall likelihood ratio test testing
for improvements over the Null model without any co-
variates remained only significant for the model includ-
ing clinical covariates (p = 0,003). This suggests a better
fit for the clinical compared to the pathological
covariates.
Discussion
The present retrospective analysis of a surgical cohort
being treated in a multimodality treatment concept
showed a high correlation between preoperative assessed
CT tumor volume and the actual tumor volume of the
resected tumor specimen proposing a realistic reflection
of CT data for preoperative decision-making. Further-
more, cTV was confirmed in alignment with previous
studies to have a prognostic impact on OS. To our
knowledge, pathological tumor weight and volume were
assessed for the first time and being correlated with clin-
ical measurements.
In 1998, Pass and colleagues [13] described a strong
correlation between pre-operative CT tumor volume
and prognosis being OS, progression-free survival and
also with nodal spread. Moreover, they found an associ-
ation between the cTV and the IMIG stage [13]. This
was the first reported attempt of using the volumetric
assessment for stratifying MPM patients. However, the
manual tumor segmentation and the need for a time-
consuming measurement, as well as the inter observer
variability made the common use of cTV quite impracti-
cal. In 2010, Fan Liu and colleagues [14], benefitted from
the use of semiautomatic computer method and imaging
viewer system, for implementing a computer-aided
tumor volume quantification. In their study, they
grouped the TNM stages in “low stage” (I and II) and
“high stage” (III and IV), finding a significant correlation
between the cTV and the clinical TNM staging groups.
However, this did not correlate when comparing the
cTV with the pathological TNM stage. Nevertheless,
they concluded that cTV variation after induction
chemotherapy was a good predictor of the survival and
computer-aided volume measurement could assist the
radiologist in the precise tumor measurement. A group
from the Harvard Medical School in Boston, embraced
this principle and published two studies in 2012 [15]
and 2018 [11]. The authors consistently focused on the
prognostic performance of the cTV and they found a
correlation between it and survival in MPM patients. In
the second study [11], along with cTV, they evaluated in
the same model, also a second descriptor of the MPM
tumor burden: the maximal fissural thickness. After test-
ing different models, they concluded that the combin-
ation of the cTV and the maximal fissural thickness
performed better compared to the clinical AJCC staging
even though there was no statistical difference in per-
formance with the pathological AJCC staging [9, 12].
Table 2 CT-derived and actual measurements
Covariate Overall
n 53 median [range]
Tumor volume (ml) 530 [130–1000]
Tumor weight (g) 485 [95–982]
CT tumor thickness (mm) 9 [3.1–39.8]
CT tumor volume (ml) 77.2 [1.5–787]
pre upper 6.85 [2–50.7]
pre middle 5.35 [1.5–33.8]
pre lower 7.7 [2.5–58.7]
pre max 10.8 [2.8–58.7]
pre sum 21.2 [8.6–90.6]
post upper 5.85 [1.7–37.3]
post middle 5.3 [1.8–29.4]
post lower 8.4 [2.2–39.8]
post sum 18.75 [8.3–72.2]
Tumor thickness thickest area 1.2 [0.2–7]
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Overall, according to the literature and to our study
results, pre-operative tumor burden may play a consist-
ent role in the prognosis of patients with MPM. On the
other hand, there is a consistent lack in correspondence
between the clinical descriptors and the pathologic sta-
ging. This consideration supports the discussion around
the evolving classification of the MPM in looking for in-
corporating different descriptors, to improve the clinical
usefulness of the staging. Nowak at al [9], in their pro-
posal for revisions of the T descriptors, proposed the
measurement of pleural thickness as possible additional
variable to incorporate into future staging. In our
population, we found a correlation between cTT and
IMIG stage, however, this variable failed to be retained
in the multivariable analysis and showed to have no as-
sociation with the OS. However, the combination of CT
tumor volume and thickness showed a better result in
potentially predicting survival time.
It is important to underline that, unlike most solid tu-
mors, which are suitable for a robust mono-dimensional
measurement, the morphology of MPM, and almost
constant presence of pleural effusion, may complicate
the quantification (Fig. 5). Magnetic resonance imaging
(MRI) for preoperative staging for patients with
Fig. 1 The distribution free Wilcoxon-Mann-Whitney test was used. IMIG stage low includes stage I and II, high includes stage III and IV. cTT
(computed tomography derived tumor thickness)
Fig. 2 The distribution free Wilcoxon-Mann-Whitney test was used. IMIG stage low includes stage I and II, high includes stage III and IV. cTV
(computed tomography derived tumor volume)
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malignant pleural mesothelioma is more precise than
CT derived clinical staging especially in context of the
assessment for surgical resection because of its higher
resolution for soft tissue and the evaluation of invasion
of the thoracic endothoracic fascia, chest wall, dia-
phragm, and mediastinal fat. Because of these reasons
the British Thoracic Society (BTS) recommends thoracic
MRI in the decision making for a multimodality therapy
approach including surgical resection [16]. Specificity
and sensitivity of the MRI show an association with the
tumor stage, where both are increasing with the higher
tumor stage (87.5% for T2 and specificity of 91% and
sensitivity of 100% for T3 stage) [17]. This may result in
a general upstaging due to a better distinction of chest
wall and mediastinal invasion and a better patient
selection for a potential macroscopic complete resection
[18]. The cTT may be better reflected on MRI. This may
be one of the reasons for the lack of prognostic signifi-
cance of cTT in our population due to the evaluation on
a CT scan and additionally to the small sample size.
On the other side, CT imaging plays a historical role
in malignant pleural mesothelioma staging as it is widely
accessible and has a lower inter observer variability com-
pared to MRI. Furthermore, CT scan is the most fre-
quently used technique and radiologists have a broader
experience in their evaluation. Although the extent of
chest wall and/or mediastinal invasion is less accurate
with CT derived imaging than MRI, intrathoracic lymph-
adenopathy and extrathoracic spread can be better de-
tected, respiratory and cardiac motion artefacts are less
Fig. 3 A non-parametric “loss” fit is shown as a linear relationship is not presumed. cTT = computed tomography derived tumor thickness, cTV =
computed tomography derived tumor volume, pTV = pathological tumor volume
Fig. 4 Median OS 23.7 months (CI 95%: LCL-UCL: 17.9–34)
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frequently in CT than MRI [19]. Limitation of the MRI
is the long acquisition time that are also the cause of the
aforementioned artefacts [20].
When it comes to the assessment of CT derived tumor
volume its role in preoperative evaluation is manifest [15].
As described previously, several groups proofed the correl-
ation of cTV and T-status and their impact on OS and
PFS [1]. They showed, that large volumes are associated
with nodal spread as well as post resection residual tumor
burden and that they may predict outcome [21, 22].
The missing impact of pTV and pTW on OS might be
explained by the fact, that the tumor burden per se is
not decisive as a prognosticator. It is also the type and
localization of the tumor’s distribution as well as the
lymph node involvement that may affect the patient’s
survival.
Nevertheless, it has not been yet implemented in
current staging systems due to inter observer variability
and lack of reproducibility [16, 23, 24].
Limitations
Our study has some limitations. Its retrospective nature
carries an inherent bias. We have also to consider that
our data are extracted from a purely surgical MPM
population. Additionally, computed tomography gener-
ated T-stage suffers from the fact that in some cases not
all measurements (lower, middle, upper) were available.
Nevertheless, a minimum of measurements at two levels
were required. This may result in a less representative
value of tumor thickness measurement. Additionally,
drawing any conclusion for the correlation of cTV and
pTV is difficult, as the median volume of the specimen
is much greater. This is due to the fact that resected dia-
phragm and pericardium, in case of EPD are part of it.
Conclusions
In conclusion, our study supports the prognostic rele-
vance of tumor burden in MPM patients, as it showed a
high correlation between preoperative assessed CT
tumor volume and the actual tumor volume of the
resected tumor specimen. Computed derived tumor vol-
ume proposes a realistic reflection of CT data for pre-
operative decision making. The use of semi-automatic
user-friendly software for accurate three-dimensional
tumor evaluation is useful to implement CT descriptors
in patients’ evaluation. This might improve the actual
staging system and contribute to achieve a more accur-
ate stratification of patients. Conformity between differ-
ent medical centers might profit as well. Even if our
results do not have the power for proposing a change in
the staging system, they can serve as support for further
studies.
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